Muscle & Nerve

Article	Citations
Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double‐blind, placebo‐controlled	94
Small fiber neuropathy associated with SARS‐CoV‐2 infection	81
Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study	70
A randomized placebo‐controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis	56
Parsonage Turner syndrome after COVID‐19 vaccination	56
Post COVID‐19 vaccine small fiber neuropathy	55
Multisystem proteinopathy: Where myopathy and motor neuron disease converge	39
Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy	39
Safety, feasibility, and efficacy of strengthening exercise in Duchenne muscular dystrophy	36
Survival analyses from the CENTAUR trial in amyotrophic lateral sclerosis: Evaluating the impact of treatment crossover on outcomes	35
Neurofilament light‐chain response during therapy with antisense oligonucleotide tofersen in SOD1‐related ALS: Treatment experience in clinical practice	33
Traumatic injury to peripheral nerves	33
COVID‐19 Vaccination in Autoimmune Diseases (COVAD) study: Vaccine safety in idiopathic inflammatory myopathies	33
Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5‐year update of theNURTUREstudy	32
(−)‐Epicatechin induces mitochondrial biogenesis and markers of muscle regeneration in adults with Becker muscular dystrophy	31
COVID‐19 in patients with myasthenia gravis: Epidemiology and disease course	31
TS‐HDS and FGFR3 antibodies in small fiber neuropathy and Dysautonomia	31
Tocilizumab is safe and tolerable and reduces C‐reactive protein concentrations in the plasma and cerebrospinal fluid of ALS patients	30
Time to diagnosis of Duchenne muscular dystrophy remains unchanged: Findings from the Muscular Dystrophy Surveillance, Tracking, and Research Network, 2000‐2015	29
Utilization of MG‐ADL in myasthenia gravis clinical research and care	28
Combination therapy with onasemnogene and risdiplam in spinal muscular atrophy type 1	28
Nerve biopsy: Current indications and decision tools	28
Muscle fiber size in healthy children and adults in relation to sex and fiber types	27
Melatonin may slow disease progression in amyotrophic lateral sclerosis: Findings from the Pooled Resource Open‐Access ALS Clinic Trials database	27
Doctor—Should I get the COVID‐19 vaccine? Infection and immunization in individuals with neuromuscular disorders	26

Non‐length‐dependent small fiber neuropathy: Not a matter of stockings and gloves	26
Myasthenic crisis	25
Neuromuscular amyloidosis: Unmasking the master of disguise	25
Assessment of dysarthria and dysphagia in patients with amyotrophic lateral sclerosis: Review of the current evidence	24
COVID‐19‐associated myositis may be dermatomyositis	24
Regenerative peripheral nerve interface free muscle graft mass and function	23
Clinical exome sequencing in the diagnosis of pediatric neuromuscular disease	23
Gold Coast diagnostic criteria: Implications for ALS diagnosis and clinical trial enrollment	22
Different trajectories in upper limb and gross motor function in spinal muscular atrophy	21
Acute‐onset polyradiculoneuropathy after SARS‐CoV2 vaccine in the West and North Midlands, United Kingdom	21
Anti‐cN1A antibodies do not correlate with specific clinical, electromyographic, or pathological findings in sporadic inclusion body myositis	21
Nivolumab‐associated Lambert‐Eaton myasthenic syndrome and cerebellar dysfunction in a patient with a neuroendocrine tumor	20
Telemedicine visits in myasthenia gravis: Expert guidance and the Myasthenia Gravis Core Exam (MG‐CE)	20
Skeletal muscle magnetic resonance imaging in Pompe disease	20
The Duke myasthenia gravis clinic registry: I. Description and demographics	20
Association of diaphragm thickness and echogenicity with age, sex, and body mass index in healthy subjects	19
Influence of ultrasound focus depth on the association between echo intensity and intramuscular adipose tissue	18
Short‐term effect of low‐dose rituximab on myasthenia gravis with muscle‐specific tyrosine kinase antibody	18
Imaging of neuralgic amyotrophy in the acute phase	18
Phase 2B randomized controlled trial of NP001 in amyotrophic lateral sclerosis: Pre‐specified and post hoc analyses	18
Smartphone data during the COVID‐19 pandemic can quantify behavioral changes in people with ALS	18
The Spinal Muscular Atrophy Health Index: A novel outcome for measuring how a patient feels and functions	17
Effects of mexiletine on hyperexcitability in sporadic amyotrophic lateral sclerosis: Preliminary findings from a small phase II randomized controlled trial	17
Risdiplam in non‐sitter patients aged 16 years and older with 5q spinal muscular atrophy	17
Small fiber neuropathy: Swiss cohort characterization	17
Early experiences of nusinersen for the treatment of spinal muscular atrophy: Results from a large survey of patients and caregivers	17
Porphyric neuropathy	17
Clinical profile and impact of comorbidities in patients with very‐late‐onset myasthenia gravis	17
Minimal important differences and self‐identifying treatment response in chronic inflammatory demyelinating polyneuropathy	16
Walking activity in a large cohort of boys with Duchenne muscular dystrophy	16
The use of eculizumab in ventilator‐dependent myasthenia gravis patients	16
A double‐blind placebo‐controlled pilot study of immunoglobulin for small fiber neuropathy associated with TS‐HDS and FGFR‐3 autoantibodies	16
Gender differences in clinical outcomes in myasthenia gravis: A prospective cohort study	16
The Notch signaling pathway in skeletal muscle health and disease	15
Estimating myofiber cross‐sectional area and connective tissue deposition with electrical impedance myography: A study in D2‐mdx mice	15
Immune‐mediated necrotizing myopathy: Unusual presentations of a treatable disease	15
Utility of neuromuscular ultrasound in the investigation of common mononeuropathies in everyday neurophysiology practice	14
A temporal association between COVID‐19 vaccination and immune‐mediated necrotizing myopathy	14
Variability in electrodiagnostic findings associated with neurogenic thoracic outlet syndrome	14
Long‐term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1/2a nonrandomized trial	14
Delays in pulmonary decline in eteplirsen‐treated patients with Duchenne muscular dystrophy	14
Motor axonal neuropathy associated with GNE mutations	14
Risdiplam for the treatment of adults with spinal muscular atrophy: Experience of the Northern Ireland neuromuscular service	14
A standardized ultrasound approach in neuralgic amyotrophy	14
Diagnostic accuracy of gray scale muscle ultrasound screening for pediatric neuromuscular disease	14
Screening for oropharyngeal dysphagia in adult patients with neuromuscular diseases using the Sydney Swallow Questionnaire	14
Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study	13
Knowledge and perceptions of theCOVID‐19 pandemic among patients with myasthenia gravis	13
Is it time to revisit the Boston Carpal Tunnel Questionnaire? New insights from a Rasch model analysis	13
The cumulative incidence of dysphagia and dysphagia‐free survival in persons diagnosed with amyotrophic lateral sclerosis	13

Creatine kinase‐MM concentration in dried blood spots from newborns and implications for newborn screening for Duchenne muscular dystrophy	13
Incidence and prevalence of immune‐mediated necrotizing myopathy in adults in Olmsted County, Minnesota	13
Immune‐mediated necrotizing myopathy after BNT162b2 vaccination in a patient with antibodies against receptor‐binding domain of SARS‐CoV‐2 and signal recognition particle	13
Epidemiological trends of Bell's palsy treated with steroids in Korea between 2008 and 2018	13
Post–COVID‐19 vaccine small‐fiber neuropathy and tinnitus treated with plasma exchange	13
Time is muscle: A recommendation for early treatment for preterm infants with spinal muscular atrophy	13
Body mass index associates with amyotrophic lateral sclerosis survival and metabolomic profiles	13
Role of electrodiagnosis in nerve transfers for focal neuropathies and brachial plexopathies	12
Atypical presentations of inclusion body myositis: Clinical characteristics and long‐term outcomes	12
Guidelines for genetic testing of muscle and neuromuscular junction disorders	12
Elevation of fast but not slow troponin I in the circulation of patients with Becker and Duchenne muscular dystrophy	12
Laboratory monitoring of nusinersen safety	12
Is cerebrospinal fluid amyloid‐β42 a promising biomarker of response to nusinersen in adult spinal muscular atrophy patients?	12
Association of genetic mutations and loss of ambulation in childhood‐onset dystrophinopathy	12
Age‐related changes in appendicular lean mass in males with Duchenne muscular dystrophy: A retrospective review	12
Nusinersen by subcutaneous intrathecal catheter for symptomatic spinal muscular atrophy patients with complex spine anatomy	12
Myasthenia gravis exacerbation in association with antibody overshoot following plasmapheresis	12
Assessment of feasibility and utility of universal referral to specialty palliative care in a multidisciplinary amyotrophic lateral sclerosis clinic: A cohort study	12
Sensory nerve regeneration and reinnervation in muscle following peripheral nerve injury	12
COVID‐19–accelerated disease progression in two patients with amyotrophic lateral sclerosis	11
Gold Coast criteria expand clinical trial eligibility in amyotrophic lateral sclerosis	11
Antecedent infections and vaccinations in chronic inflammatory demyelinating polyneuropathy: A European collaborative study	11
Evidence‐based guideline: Neuromuscular ultrasound for the diagnosis of ulnar neuropathy at the elbow	11
Thymoma pathology and myasthenia gravis outcomes	11
Temporal evolution of nerve conduction study abnormalities in anti‐myelin‐associated glycoprotein neuropathy	11
Reinnervation as measured by the motor unit size index is associated with preservation of muscle strength in amyotrophic lateral sclerosis, but not all muscles reinnervate	11
Anti‐calcitonin gene–related peptide monoclonal antibodies for neuropathic pain in patients with migraine headache	11
An expanded access protocol of RT001 in amyotrophic lateral sclerosis—Initial experience with a lipid peroxidation inhibitor	11
Quantitative muscle MRI as a sensitive marker of early muscle pathology in myotonic dystrophy type 1	11
Selecting disease‐modifying medications in 5q spinal muscular atrophy	11
Cardiac and pulmonary findings in dysferlinopathy: A 3‐year, longitudinal study	11
The best and worst of times in therapy development for myasthenia gravis	10
Muscle architecture is associated with muscle fat replacement in Duchenne and Becker muscular dystrophies	10
Challenges in diagnosing coexisting ocular myasthenia gravis and thyroid eye disease	10
Assessment of thrombocytopenia, sleep apnea, and cardiac involvement in GNE myopathy patients	10
An integrated approach to the evaluation of patients with asymptomatic or minimally symptomatic hyperCKemia	10
Using machine learning algorithms to enhance the diagnostic performance of electrical impedance myography	10
Clinical course and outcome of an outpatient clinic population with myasthenia gravis and COVID‐19	10
Predictors, outcome and characteristics of oropharyngeal dysphagia in idiopathic inflammatory myopathy	10
Relative effects of forced vital capacity and ALSFRS‐R on survival in ALS	10
Retrospective study on the safety of COVID‐19 vaccination in myasthenia gravis	10
Infection rate, mortality and characteristics of veterans with amyotrophic lateral sclerosis with COVID‐19	10
Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment	10
Subcutaneous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy	10
Using MRI to quantify skeletal muscle pathology in Duchenne muscular dystrophy: A systematic mapping review	10
Telephone consultation for myasthenia gravis care during the COVID‐19 pandemic: Assessment of a novel virtual myasthenia gravis index	9
Hereditary myopathies associated with hematological abnormalities	9
Nodal conduction block: A unifying concept	9
hnRNP L is essential for myogenic differentiation and modulates myotonic dystrophy pathologies	9
Retrospective analysis of safety and outcomes of rituximab for myasthenia gravis in patients ≥65 years old	9
Cortical excitability threshold can be increased by the AMPA blocker Perampanel in amyotrophic lateral sclerosis	9
Autoantibodies in Japanese patients with ocular myasthenia gravis	9
Hourglass‐like constrictions on MRI are common in electromyography‐confirmed cases of neuralgic amyotrophy (Parsonage–Turner syndrome): A tertiary referral center experience	9
Home‐based gait analysis as an exploratory endpoint during a multicenter phase 1 trial in limb girdle muscular dystrophy type R2 and facioscapulohumeral muscular dystrophy	9
Small fiber neuropathy underlying dysautonomia in COVID‐19 and in post‐SARS‐CoV‐2 vaccination and long‐COVID syndromes	9
Single fiber electromyography and measuring jitter with concentric needle electrodes	9
Occurrence of symptoms in different stages of Duchenne muscular dystrophy and their impact on social participation	9
Management of Spinal Muscular Atrophy in the Adult Population	9
Updated consensus statement: Intravenous immunoglobulin in the treatment of neuromuscular disorders report of the AANEM ad hoc committee	9
Motor unit number index: A potential electrophysiological biomarker for pediatric spinal muscular atrophy	9
The senile hand: Age effects on intrinsic hand muscle CMAP amplitudes influence split‐hand index calculations	8
Quantitative T2‐mapping magnetic resonance imaging for assessment of muscle motor unit recruitment patterns	8
Randomized trial of inosine for urate elevation in amyotrophic lateral sclerosis	8
Pulmonary care for ALS: Progress, gaps, and paths forward	8
Feasibility and reliability of MScanFit motor unit number estimation in peroneus longus muscle	8
Amyotrophic lateral sclerosis mimics	8
Visual versus quantitative analysis of muscle ultrasound in neuromuscular disease	8
Clinical and neurophysiological biomarkers of disease progression in amyotrophic lateral sclerosis	8
The effect of oral bisphosphonate therapy on vertebral morphometry and fractures in patients with Duchenne muscular dystrophy and glucocorticoid‐induced osteoporosis	8
Fasciculation frequency at the biceps brachii and brachialis muscles is associated with amyotrophic lateral sclerosis disease burden and activity	8
Longitudinal comparison of the self‐entry Amyotrophic Lateral Sclerosis Functional Rating Scale‐Revised (ALSFRS‐RSE) and Rasch‐Built Overall Amyotrophic Lateral Sclerosis Disability Scale (	8
Ultrasound assisted lumbar intrathecal administration of nusinersen in adult patients with spinal muscular atrophy: A case series	8
Safety and outcomes with efgartigimod use for acetylcholine receptor‐positive generalized myasthenia gravis in clinical practice	8
Genotype‐related respiratory progression in Duchenne muscular dystrophy—A multicenter international study	8
Causes and consequences of diagnostic delay in Guillain‐Barré syndrome in a UK tertiary center	8
Reliability and construct validity of the Duchenne Video Assessment	8
Dominant and recessive congenital myasthenic syndromes caused by SYT2 mutations	8
Creating stem cell‐derived neuromuscular junctions in vitro	8
Evaluation of effects of continued corticosteroid treatment on cardiac and pulmonary function in non‐ambulatory males with Duchenne muscular dystrophy from MD STARnet	8
Randomized phase 2 study ofACE‐083, amuscle‐promotingagent, in facioscapulohumeral muscular dystrophy	8

Krüppel‐like factor 10 regulates the contractile properties of skeletal muscle fibers in mice	8
Hyperlactacidemia as a risk factor for intensive care unit‐acquired weakness in critically ill adult patients	8
Longitudinal changes in respiratory and upper limb function in a pediatric type III spinal muscular atrophy cohort after loss of ambulation	8
Early initiation of riluzole may improve absolute survival in amyotrophic lateral sclerosis	8
Assessment of small fiber neuropathy in patients carrying the non‐classical Fabry variant p.D313Y	8
Investigating the possible association between NLRP3 gene polymorphisms and myasthenia gravis	7
Ten years of riluzole use in a tertiary ALS clinic	7
12‐Month progression of motor and functional outcomes in congenital myotonic dystrophy	7
Neuromuscular ultrasound competency assessment: Consensus‐based survey	7
Fasciculation analysis reveals a novel parameter that correlates with predicted survival in amyotrophic lateral sclerosis	7
Alterations of macrophage and neutrophil content in skeletal muscle of aged versus young mice	7
Peripheral nerve morphology and intraneural blood flow in chronic kidney disease with and without diabetes	7
Neuromuscular ultrasound findings in carpal tunnel syndrome with symptoms mainly in the nondominant hand	7
Characterization of patients with Becker muscular dystrophy by histology, magnetic resonance imaging, function, and strength assessments	7
Prognostic factors, disease course, and treatment efficacy in Duchenne muscular dystrophy: A systematic review and meta‐analysis	7
Expanding the clinical and genetic spectrum of pathogenic variants in STIM1	7
Spasticity evaluation and management tools	7
Ultrasound‐guided transforaminal approach for nusinersen delivery in adult spinal muscle atrophy patients with challenging access	7
Novel use of nusinersen as a therapeutic bridge to onasemnogene abeparvovec‐xioi in a premature neonate with type 1 spinal muscular atrophy	7
Impact of COVID‐19 on the quality of life of patients with neuromuscular disorders in the Lombardy area, Italy	7
Positive acetylcholine receptor antibody in nonmyasthenic patients	7
Obligatory role of Schwann cell‐specific erythropoietin receptors in erythropoietin‐induced functional recovery and neurogenic muscle atrophy after nerve injury	7
Posturography as a biomarker of intravenous immunoglobulin efficacy in chronic inflammatory demyelinating polyradiculoneuropathy	7
A phase Ib/IIa, open‐label, multiple ascending‐dose trial of domagrozumab in fukutin‐related protein limb‐girdle muscular dystrophy	7
Safety and activity of anti‐CD14 antibody IC14 (atibuclimab) in ALS: Experience with expanded access protocol	7
Lateral femoral cutaneous neuropathy caused by prone positioning to treat COVID‐19‐associated acute respiratory distress syndrome	7
Nerve ultrasound evaluation of Guillain‐Barré syndrome subtypes in northern China	7
Muscle biopsy and MRI findings in ANO5‐related myopathy	7
Immune‐mediated neuromuscular complications of graft‐versus‐host disease	7
Endocannabinoids and related lipids in serum from patients with amyotrophic lateral sclerosis	6
Autologous hematopoietic stem cell transplant for the treatment of refractory myasthenia gravis with anti‐muscle specific kinase antibodies	6
Quantitative analysis of myokymic discharges in radiation versus nonradiation cases	6
Delivering multidisciplinary neuromuscular care for children via telehealth	6
Asymptomatic common extensor tendon pathology in patients with carpal tunnel syndrome	6
Effects of exercise on muscle reinnervation and plasticity of spinal circuits in rat sciatic nerve crush injury models with different numbers of crushes	6
Systemic manifestations and symptom burden of facioscapulohumeral muscular dystrophy in a referral cohort	6
Motion sensor‐acquired reachable workspace correlates with patient‐reported upper extremity activities of daily living (ADL) function in facioscapulohumeral dystrophy	6
Nerve ultrasound studies in POEMS syndrome	6
Utility of transoral motion‐mode ultrasonography to detect tongue fasciculation in patients with amyotrophic lateral sclerosis	6
One‐year follow‐up of disease burden and medication changes in patients with myasthenia gravis: From the MG Patient Registry	6
Feasibility of simultaneous high‐resolution anatomical and quantitative magnetic resonance imaging of sciatic nerves in patients with Charcot–Marie–Tooth type 1A (	6
T‐box transcription factor 21 is expressed in terminal Schwann cells at the neuromuscular junction	6
Small Fiber Neuropathy and SARS‐CoV‐2 Infection. Another piece in the long COVID puzzle?	6
Role of complement components in vasculitic neuropathy associated with systemic lupus erythematosus and rheumatoid arthritis	6
Safety of mRNA COVID‐19 vaccines in patients with well‐controlled myasthenia gravis	6
Identifying a patient‐centered outcome measure for a comparative effectiveness treatment trial in myasthenia gravis	6
The long exercise test as a functional marker of periodic paralysis	6
Ultrasound guidance may have advantages over landmark‐based guidance for some nerve conduction studies	6
Validation of myasthenia gravis diagnosis in the older Medicare population	6
Design and pilot testing of a 26‐gauge impedance‐electromyography needle in wild‐type and ALS mice	6
Autoantibody profile in myasthenia gravis patients with a refractory phase	6
The outcomes and experience of pregnancy in limb girdle muscular dystrophy type R9	6
Which combined nerve conduction study scores are best suited for polyneuropathy in diabetic patients?	6
Impact of subcutaneous immunoglobulin on quality of life in patients with chronic inflammatory demyelinating polyneuropathy previously treated with intravenous immunoglobulin	6
Anatomical variations of the superficial branch of the radial nerve and the dorsal branch of the ulnar nerve: A detailed electrophysiological study	6
Associations of neuralgic amyotrophy with COVID‐19 vaccination: Disproportionality analysis using the World Health Organization pharmacovigilance database	6
Nerve ultrasound detects abnormally small nerves in patients with spinal and bulbar muscular atrophy	5
Determinants and functional impacts of diaphragmatic involvement in patients with inclusion body myositis	5
Fiber optic Raman spectroscopy for the evaluation of disease state in Duchenne muscular dystrophy: An assessment using the mdx model and human muscle	5
Ultrasound‐guided motor unit scanning electromyography	5
Risk factors for lumbosacral radiculoplexus neuropathy	5
What do people affected by amyotrophic lateral sclerosis want from health communications? Evidence from the ALS Talk Project	5
Suicide among veterans with amyotrophic lateral sclerosis	5
Three‐dimensional quantitative muscle ultrasound in a healthy population	5
Harnessing the power of the electronic health record for ALS research and quality improvement: CReATe CAPTURE‐ALS and the ALS Toolkit	5
Laryngospasm in amyotrophic lateral sclerosis	5
Peripheral neuropathies associated with DNA repair disorders	5
Incidence of amyotrophic lateral sclerosis in older adults	5
Voluntary and magnetically evoked muscle contraction protocol in males with Duchenne muscular dystrophy: Safety, feasibility, reliability, and validity	5
Non‐dystrophic myotonia: 2‐year clinical and patient reported outcomes	5
Musculoskeletal mimics of cervical radiculopathy	5
Palliative care in amyotrophic lateral sclerosis clinics: A survey of NEALS consortium membership	5
Myonuclear apoptosis via cleaved caspase‐3 upregulation is related to macrophage accumulation underlying immobilization‐induced muscle fibrosis	5
A patient‐focused survey to assess the effects of the COVID‐19 pandemic and social guidelines on people with muscular dystrophy	5
Opinions on Pneumocystis jirovecii prophylaxis in autoimmune neuromuscular disorders	5
MeRef: Multivariable extrapolated reference values in motor nerve conduction studies	5
Changes in motor function in Duchenne muscular dystrophy patients after travel restrictions due to COVID‐19	5
Cerebrospinal fluid characteristics of patients treated with intrathecal nusinersen for spinal muscular atrophy	5
Intraneural ganglion cysts originating from the hip joint: A single‐center experience	5
MScanFit motor unit number estimation of human anconeus muscle	5
Subepidermal Schwann cell counts correlate with skin innervation – an exploratory study	5
Effects of cardiac medications on ventricular function in patients with Duchenne muscular dystrophy–related cardiomyopathy	5
Whole‐Body MRI in Limb Girdle Muscular Dystrophy Type R1/2A: Correlation With Clinical Scores	5
Assessing perspectives of disease burden and clinically meaningful changes using the Spinal Muscular Atrophy Health Index in adolescents and young adults	5
Correlation of muscle ultrasound with clinical and pathological findings in idiopathic inflammatory myopathies	5
Effect of exercise training on functional capacity and body composition in myotonic dystrophy type 2 patients	5
Appetite and quality of life in amyotrophic lateral sclerosis: A scoping review	5
Pain as a significant symptom in patients with periodic paralysis—A cross‐sectional survey	5
Quantitative muscle analysis in facioscapulohumeral muscular dystrophy usingwhole‐body fat‐referenced MRI: Protocol development, multicenter feasibility, and repeatability	5
Diagnostic yield of advanced genetic testing in patients with hereditary neuropathies: A retrospective single‐site study	5
Virtual neuromuscular ultrasound courses during COVID‐19 pandemic: Leveraging technology to enhance learning opportunities	5
Sonographic reference values of nerve size in children: A systematic review and meta‐analysis	5
Assessment of clinical factors affecting outcome of myasthenia gravis	5
Needs of persons living withALSat home and their family caregivers: A scoping review	5
Long‐term efficacy and safety of dichlorphenamide for treatment of primary periodic paralysis	5